中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 12
Dec.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(12): 2750-2754

Value of von Willebrand factor antigen-to-albumin ratio and glycocalicin index in predicting esophageal varices in hepatitis B cirrhosis

DOI: 10.3969/j.issn.1001-5256.2022.12.013
  • a.

    Department of Medical Laboratory, The Affiliated Hospital of Yanbian University, Yanji, Jilin 133000, China

  • b.

    Department of Gastroenterology, The Affiliated Hospital of Yanbian University, Yanji, Jilin 133000, China

  • c.

    Department of Ultrasonography, The Affiliated Hospital of Yanbian University, Yanji, Jilin 133000, China

Research funding:

Applied Foundation Research Project of Yanbian University (2020-45)

More Information
  • Corresponding author: PIAO Meihua, 2224595359@qq.com (ORCID: 0000-0003-2621-6590)
  • Received Date: 2022-06-21
  • Accepted Date: 2022-07-25
  • Published Date: 2022-12-20
    Abstract
  •   Objective  To investigate the clinical value of von Willebrand factor antigen-to-albumin ratio (VAR) score and glycocalicin index (GCI) score in predicting the development and classification of esophageal varices in comparison with von Willebrand factor antigen-to-platelet ratio (VITRO) score.  Methods  A retrospective analysis was performed for 146 patients with hepatitis B cirrhosis who were hospitalized from April 2020 to December 2021, and esophageal varices (EV) was diagnosed and graded with the results of gastroscopy as the standard. VITRO, VAR, and GCI were calculated, and their association with EV was analyzed. The t-test was used for comparison of normally distributed continuous data between two groups, and a one-way analysis of variance was used for comparison between multiple groups; the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups. The chi-square test was used for comparison of categorical data between groups. A logistic regression model analysis was used to identify the predictive factors for EV, and the receiver operating characteristic (ROC) curve was used to evaluate the diagnostic accuracy of each index.  Results  Gastroscopy showed 54 patients without EV, 30 with mild EV, 33 with moderate EV, and 29 with severe EV. The patients with EV had significantly higher VAR and GCI scores than those without EV (t=-5.819 and -3.449, both P < 0.001). The linear regression analysis showed that VAR and GCI increased with the increase in EV grade (P=0.002 and 0.005). The multivariate logistic regression analysis showed that VAR (odds ratio [OR]=1.46, 95% confidence interval [CI]: 1.21-1.75, P < 0.001) and GCI (OR=1.84, 95%CI: 1.22-2.77, P=0.003) were independently associated with EV. VITRO score had an area under the ROC curve (AUC) of 0.718 in diagnosing EV and 0.863 in diagnosing severe EV, with the optimal cut-off values of 2.77 and 5.37, respectively. VAR and GCI had an AUC of 0.745 and 0.710, respectively, in diagnosing EV, with the optimal cut-off values of 8.88 and 1.70, respectively; VAR and GCI had an AUC of 0.755 and 0.787, respectively, in diagnosing severe EV, with the optimal cut-off values of 9.81 and 2.00, respectively. VAR combined with GCI had significantly better efficacy than VITRO in diagnosing EV (P=0.009), with an AUC of 0.808, a sensitivity of 55.43%, and a specificity of 94.44%; VAR combined with GCI had an AUC of 0.869 in diagnosing severe EV, which was similar to VITRO (P=0.421).  Conclusion  VAR and GCI scores are potential noninvasive markers for the prediction and risk stratification of EV in patients with hepatitis B cirrhosis.

     

    • FullText(HTML)
  • loading
    • References(13)
  • [1]
    Chinese Society of Spleen and Portal Hypertension Surgery, Chinese Society of Surgery, Chinese Medical Association. Expert consensus on diagnosis and treatment of esophagogastric variceal bleeding in cirrhotic portal hypertension (2015 edition)[J]. Chin J Pract Surg, 2015, 35(10): 1086-1090. DOI: 10.7504/CJPS.ISSN1005-2208.2015.10.16.

    中华医学会外科学分会门静脉高压症学组. 肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2015)[J]. 中国实用外科杂志, 2015, 35(10): 1086-1090. DOI: 10.7504/CJPS.ISSN1005-2208.2015.10.16.
    [2]
    POISSON J, LEMOINNE S, BOULANGER C, et al. Liver sinusoidal endothelial cells: Physiology and role in liver diseases[J]. J Hepatol, 2017, 66(1): 212-227. DOI: 10.1016/j.jhep.2016.07.009.
    [3]
    IWAKIRI Y, GROSZMANN RJ. Vascular endothelial dysfunction in cirrhosis[J]. J Hepatol, 2007, 46(5): 927-934. DOI: 10.1016/j.jhep.2007.02.006.
    [4]
    XU J, LIU Y, LOU WZY, et al. The anti-liver fibrosis effect of Kangxian Ruangan prescription: A cell study based on hepatic sinusoidal capillarization[J]. J Clin Hepatol, 2020, 36(2): 319-323. DOI: 10.3969/j.issn.1001-5256.2020.02.017.

    许杰, 刘艳, 楼汪洲洋, 等. 基于肝窦毛细血管化探讨抗纤软肝方抗肝纤维化的作用机制[J]. 临床肝胆病杂志, 2020, 36(2): 319-323. DOI: 10.3969/j.issn.1001-5256.2020.02.017.
    [5]
    MAIERON A, SALZL P, PECK-RADOSAVLJEVIC M, et al. Von willebrand factor as a new marker for non-invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C[J]. Aliment Pharmacol Ther, 2014, 39(3): 331-338. DOI: 10.1111/apt.12564.
    [6]
    GARCIA-MARTINEZ R, ANDREOLA F, MEHTA G, et al. Immunomodulatory and antioxidant function of albumin stabilises the endothelium and improves survival in a rodent model of chronic liver failure[J]. J Hepatol, 2015, 62(4): 799-806. DOI: 10.1016/j.jhep.2014.10.031.
    [7]
    FENG S, FENG HF, XU J, et al. Value of FibroScan and platelet count to spleen thickness ratio in predicting the degree of esophageal and gastric varices in liver cirrhosis[J]. J Clin Hepatol, 2021, 37(12): 2819-2823. DOI: 10.3969/j.issn.1001-5256.2021.12.018.

    封爽, 冯慧芬, 徐晶, 等. 肝硬度值和血小板计数/脾脏厚径比率对肝硬化食管胃底静脉曲张程度的预测价值[J]. 临床肝胆病杂志, 2021, 37(12): 2819-2823. DOI: 10.3969/j.issn.1001-5256.2021.12.018.
    [8]
    BEER JH, BVCHI L, STEINER B. Glycocalicin: a new assay——the normal plasma levels and its potential usefulness in selected diseases[J]. Blood, 1994, 83(3): 691-702. DOI: 10.1182/blood.V83.3.691.691
    [9]
    WANG X, JIANG W, LI F, et al. Abnormal platelet kinetics are detected before the occurrence of thrombocytopaenia in HBV-related liver disease[J]. Liver Int, 2014, 34(4): 535-543. DOI: 10.1111/liv.12309.
    [10]
    HAMETNER S, FERLITSCH A, FERLITSCH M, et al. The VITRO score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a new marker for clinically significant portal hypertension in comparison to other non-invasive parameters of fibrosis including ELF test[J]. PLoS One, 2016, 11(2): e0149230. DOI: 10.1371/journal.pone.0149230.
    [11]
    SIEDLECKI CA, LESTINI BJ, KOTTKE-MARCHANT KK, et al. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor[J]. Blood, 1996, 88(8): 2939-2950. DOI: 10.1182/blood.V88.8.2939.bloodjournal8882939
    [12]
    UEMURA M, FUJIMURA Y, KO S, et al. Pivotal role of ADAMTS13 function in liver diseases[J]. Int J Hematol, 2010, 91(1): 20-29. DOI: 10.1007/s12185-009-0481-4.
    [13]
    CARACENI P, TUFONI M, ZACCHERINI G, et al. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites[J]. J Hepatol, 2021, 74(2): 340-349. DOI: 10.1016/j.jhep.2020.08.021.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1482) PDF downloads(62) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return